Last reviewed · How we verify

NCT06692842

Interactive Technological Intervention to Improve Mental Health Symptoms in Primary Health Care

Not yet recruiting NA Last updated 7 January 2026
What this trial tests

NA trial testing CONEMO App in Depression in 12,400 participants. Not yet recruiting.

Timeline
5 January 2026
Primary endpoint
31 December 2026
31 December 2028

Quick facts

Lead sponsorUniversity of Sao Paulo General Hospital
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment12,400
Start date5 January 2026
Primary completion31 December 2026
Estimated completion31 December 2028
Sites1 location across Brazil

Drugs / interventions tested

Conditions studied

Sponsor

University of Sao Paulo General Hospital

Who can join

18 and older, any sex, with Depression or Anxiety. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to implement and evaluate a technological intervention called CONEMO to treat depressive symptoms, anxiety, and insomnia in adults who use primary health care services. The effectiveness of this intervention has already been proven in previous research, specifically for depressive symptoms. Implementation will occur in 28 basic health units in the municipalities of Indiatuba and Jaguariúna in the interior of São Paulo. All eligible residents of the cities will be invited to participate.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Depression

Currently open trials in the same condition.

Other University of Sao Paulo General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06692842.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing